A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Quizartinib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 16 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 07 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.